Chinese biotechnology company Sino Biological Inc (SZ:301047) announced on Wednesday that it has launched the 2026-2027 Northern Hemisphere influenza vaccine strain antigens to accelerate vaccine development.

This follows the World Health Organization's (WHO) recommendations for the 2026-2027 Northern Hemisphere influenza vaccine composition, highlighting the continued spread of A(H3N2) subclade K and emerging B/Victoria lineage strains.

To support global influenza vaccine research and development, Sino Biological has introduced an extensive portfolio of recombinant antigens for the 2026-2027 influenza vaccine strains, including A/Missouri/11/2025 (H1N1) HA Trimer (purity greater than 90% verified by SEC-MALS), NA, and NP proteins.

Dr. Rob Burgess, chief business officer at Sino Biological US, said: "Our mission is to provide the scientific community with the highest quality tools as rapidly as possible when infectious disease evolution threatens global health preparedness."